Finally, recently promising results were shown for temelimab, a monoclonal immunoglobulin (Ig) G4, in the treatment for MS, targeting the HERV-W-Env, while its potential efficacy in type I diabetes mellitus has also been indicated [100,101]. The gene discussed is ERVW-1; the disease is type 1 diabetes mellitus.